Latest news with #as
Yahoo
30-07-2025
- Sport
- Yahoo
Vancouver Canucks Coaches' Playing Careers: Daniel Sedin
Welcome back to The Hockey News - Vancouver Canucks site's Coaches as Players series. Last time, we looked at assistant coach Brett McLean's time with the Chicago Blackhawks, Colorado Avalanche, and Florida Panthers. Today's player needs no introduction to the Canucks fanbase, so let's dive right into player development coach Daniel Sedin's historic career with Vancouver.
Yahoo
16-07-2025
- Business
- Yahoo
Caylent Renews Strategic Collaboration Agreement with AWS to Deliver Industry-Specific GenAI Solutions
Creation of new industry principal strategists to shape go-to-market strategies and solutions to accelerate customer outcomes NEW YORK, July 16, 2025 /PRNewswire/ -- Caylent, an Amazon Web Services (AWS) Premier Tier Services Partner, today announced a renewed strategic collaboration agreement (SCA) with AWS. The agreement expands investment in AI and industry-specific solutions to accelerate enterprise cloud adoption and generative AI (GenAI) enablement across high-growth verticals including: healthcare and life sciences, financial services, media and entertainment, sports, Software as a Service (SaaS) and Independent Software Vendors (ISVs), travel and hospitality, energy, automotive and manufacturing, education technology and more. As part of this agreement, Caylent is launching 16 new industry-tailored GenAI solutions and significantly growing its industry and AI-focused teams with the creation of new Industry Principal Strategists. These domain experts understand the unique regulatory, operational, and data challenges of each vertical and will guide customers through complex modernization with tailored roadmaps and measurable outcomes. The first four GenAI solutions launching are: Intelligent Document Processing for Financial Services – Transforms financial documents into actionable insights with AI pipelines that automate intake, extraction, and regulatory compliance. Video Understanding for Media & Entertainment – Transforms video into strategic insights with AI that analyzes visuals, audio, and text to drive personalization, engagement, and monetization. Clinical Trial Design Optimizer – Brings precision and speed to trial design by integrating real-world data, AI insights, and regulatory precedent. Cuts trial execution costs 10-20% and accelerates overall development timelines by 5-10% Clinical Document Writer – Reduces regulatory submission documentation time by 40% and costs by 50% by automating clinical writing with AI-powered quality checks and integrated data sources. "Partnering with Caylent was instrumental in bringing our vision for the Trial Intelligence Coordinator to life. Their deep understanding of clinical research workflows, paired with their AI expertise and deep command of AWS services like Amazon Bedrock and Amazon Comprehend Medical, allowed us to build a GenAI co-pilot that transforms how imaging data is accessed, queried, and utilized," said Susan Wood, PhD, CEO at VIDA Diagnostics Inc, "With Caylent's guidance, we are now on a path to a future-ready solution that delivers real-time imaging insights, enhances collaboration across our global research teams, and sets a new bar for improving patient outcomes and therapeutic effectiveness." To expedite AI readiness, Caylent Accelerate™, the company's unique AI-powered delivery approach, unlocks previously impossible transformations and helps companies move faster, reduce costs, and create the IP they need to lead in their industries. Caylent Accelerate automates complex tasks like database migration, code translation, and compliance validation, reducing technical debt and helping enterprises build secure, scalable, AI-ready cloud environments. "As an all-in AWS Premier Tier Services Partner, we're proud to be launching new, purpose-built GenAI solutions across high-growth industries that solve real-world problems," said Caylent President and Chief Revenue Officer Val Henderson. "By adding experienced industry principals and leaders to our team, we are better equipped to guide customers through complex modernization with tailored roadmaps and measurable outcomes. This is just the beginning as we look to expand our smart solution offerings into even more industries in the future." Learn more about each solution at the links below, or visit Caylent at booth #552 at today's AWS Summit New York City. Intelligent Document Processing for Financial Services: Video Understanding for Media & Entertainment: Clinical Trial Design Optimizer: Clinical Document Writer: About CaylentAs an AWS Premier Tier Services Partner, Caylent is shaping the future where AI transforms industries responsibly and with excellence. We help companies build the solutions they need to succeed in today's market while enabling organizational evolution to thrive in a rapidly changing technology landscape. Our AI-enabled delivery methodology combined with our deep AWS experience turns our customers' ideas into impact, faster. Caylent's achievements include being named AWS Migration Consulting Partner of the Year, GenAI Industry Solution Partner of the Year, and Industry Partner of the Year - Financial Services in 2024, Application Modernization Partner of the Year in 2023, AWS Innovation Partner of the Year in 2022, and AWS Rising Star Partner of the Year in 2021. Caylent's services include migrations, modernization, custom software development and generative AI. Learn more at View original content to download multimedia: SOURCE Caylent
Express Tribune
25-06-2025
- Health
- Express Tribune
US CDC vaccine panel cites nonexistent study in Thimerosal review, sparks controversy
A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. Photo|:REUTERS/ Listen to article A review on the use of the preservative thimerosal in vaccines slated to be presented on Thursday to the US Centers for Disease Control and Prevention's outside vaccine committee cites a study that does not exist, the scientist listed as the study's author said. The report, called "Thimerosal as a Vaccine Preservative" published on the CDC website on Tuesday, is to be presented by Lyn Redwood, a former leader of the anti-vaccine group Children's Health Defense. It makes reference to a study called "Low-level neonatal thimerosal exposure: Long-term consequences in the brain," published in the journal Neurotoxicology in 2008, and co-authored by UC Davis Professor Emeritus Robert Berman. But according to Berman, "it's not making reference to a study I published or carried out." Berman said he co-authored a similarly named study in a different journal - Toxicological Sciences - that came to different conclusions than those suggested by Redwood. "We did not examine the effects of thimerosal in microglia... I do not endorse this misrepresentation of the research," he said. Reuters is the first to report on the inaccurate citation from Redwood's planned presentation. Later on Tuesday, the CDC uploaded a new version of Redwood's presentation, removing the slide that cited the Berman study. The meeting has become increasingly controversial after Health Secretary Robert F. Kennedy Jr. just weeks ago abruptly fired all previous 17 members of the expert panel and named eight new members, half of whom have advocated against vaccines. The CDC ACIP Slides have been removed from the CDC website. Will they reappear for public review before the meeting? Or is HHS "radical transparency" = hiding data and presentations from the public and presenting false data to ACIP? — Dr. David B (@boulware_dr) June 25, 2025 Kennedy, a long-time anti-vaccine activist, founded the Children's Health Defense. Both Republican US Senator Bill Cassidy of Louisiana and Democratic US Senator Patty Murray of Washington said the June 25 and 26 meeting should be postponed. The summary of the presentation suggested that there are enough thimerosal-free flu vaccines and that all pregnant women, infants and children should receive only those shots. Those aren't CDC slides. They are the slides for the presentation by Lyn Redwood, former president of Children's Health — Helen Branswell 🇨🇦 (@HelenBranswell) June 25, 2025 It was not clear if the new advisory panel would be asked to vote on such a move. Redwood's presentation was in contrast to a separate report posted by CDC staff on the CDC website on Tuesday that says evidence does not support a link between thimerosal-containing vaccines and autism or other neurodevelopmental disorders. Kennedy has long pushed a link between vaccines and autism contrary to scientific evidence. Redwood could not be immediately reached for comment. An HHS spokesman said the study being referenced was the Toxicological Sciences study Berman said was being misrepresented. The CDC's briefing material reviewed some studies on neurodevelopmental outcomes and vaccines that contain thimerosal, which has long been used in the US in multi-dose vials of medicines and vaccines to prevent germs from growing in them. According to the CDC report, 96% of all influenza vaccines in the US were thimerosal free during the 2024-25 flu season. It also added that the number of pregnant women receiving a thimerosal-containing flu vaccine has decreased over time, with only 0.3% of doses given in 2024 containing thimerosal. Kennedy wrote a book in 2014 claiming that thimerosal, a mercury-based preservative, causes brain damage. On Monday, Cassidy, who heads the US Senate Committee on Health, Education, Labor and Pensions, called for the meeting to be delayed, saying it should not take place with a relatively small panel and without a CDC director in place. Murray, a senior member and former chair of the HELP Committee, has also called for the fired panel members to be reinstated or the meeting be delayed until new members are appropriately vetted. Earlier, a newly appointed panel of vaccine advisers by US Health Secretary Robert Kennedy Jr. is now down to seven after a member withdrew ahead of the committee's first meeting, a spokesperson for the Department of Health and Human Services (HHS) said on Tuesday. Earlier in June, Kennedy had named eight members to serve on the US Centers for Disease Control and Prevention's (CDC)Advisory Committee for Immunization Practices (ACIP), including several who have advocated against vaccines, after abruptly firing all 17 members of the independent committee of experts. "Dr. Michael Ross decided to withdraw from ACIP during the financial holdings review required of members before they can start work on the committee," HHS spokesperson Andrew Nixon said in a statement, adding the committee would have benefited from his service and expertise. The New York Times first reported the news on Ross' departure. A list of voting members for the panel on the CDC's website didn't feature Ross' name as of Tuesday night. The panel, which advises the US CDC on who should get the shots after they are approved by the US Food and Drug Administration (FDA), is due to meet on June 25 and 26. It will vote on the safety of flu shots and discuss proposed recommendations for use of the combined MMRV vaccine for children under 5 years of age, according to a draft agenda on the Centers for Disease Control and Prevention's website last week. A review on the use of the preservative thimerosal in vaccines will also be presented by Lyn Redwood on Thursday during the meeting, a former leader of the anti-vaccine group Children's Health Defense.
Miami Herald
09-06-2025
- Health
- Miami Herald
JBA AI Earns FDA SaMD Recognition
A New Era of Accessible Health Monitoring GARDEN GROVE, CALIFORNIA / ACCESS Newswire / June 9, 2025 / JBA AI, the flagship health-tech division under AQ Pharmaceuticals, Inc. and JBA Brands, proudly announces several major global milestones in its mission to make preventive healthcare more accessible, intelligent, and affordable. JBA AI has been officially recognized by the United States Food and Drug Administration (FDA) as a Software as a Medical Device (SaMD). In addition, the platform has now received Class B Medical Device approval from Vietnam's Ministry of Health. These achievements affirm the platform's safety, clinical effectiveness, and international credibility. The JBA AI mobile application is already available globally for Android users and will soon be released on iOS. It enables contactless, non-invasive vital signs monitoring directly through smartphones or tablets. In just 60 seconds, the app delivers insights on over nine key health metrics. These include heart rate, heart rate variability, blood oxygen saturation, respiratory rate, stress index, and estimated glucose and blood pressure trends. This is achieved using AI-powered facial signal analysis through camera-based remote photoplethysmography technology. Expanding its impact even further, JBA AI has partnered with one of Vietnam's largest financial institutions, which serves more than 30 millions members. Together, they are preparing to launch JBA AI nationwide, making preventive health monitoring more accessible through a trusted and widespread digital network. "JBA AI is more than a health app - it's a certified medical device. Recognized by both the FDA and Vietnam's Ministry of Health," said Tracy Trang Nguyen, founder and CEO of JBA AI. "We're proud to deliver trusted, clinically guided tools for daily health monitoring worldwide." Nguyen is a Vietnamese American engineer and wellness industry leader who developed JBA AI after surviving cancer. Her personal health journey inspired her to combine advanced artificial intelligence with affordable wellness solutions. Under her leadership, JBA AI complements other products within the JBA Brands portfolio, such as GlucoTrojan, Joint Revive Fucoidan, and Vegan Collagen, to form a fully integrated health ecosystem. JBA AI is already gaining traction and is starting to expand into pharmacies, corporate wellness programs, public health campaigns, and family clinics across the United States, Vietnam, and other countries. The platform's franchise-ready model supports rapid local deployment while keeping costs low and impact high. It is designed to help people monitor their health in real-time, without the need for needles, wearable devices or clinic visits. JBA AI is currently welcoming franchisees, affiliates, and institutional partners to help bring this technology to communities around the world. Whether at home or in partnership with healthcare providers, JBA AI is redefining preventive care through data-driven technology and a compassionate approach to well-being. Contact Information Catherine Marino Marketing Managercat@ 714 903 1009 SOURCE: AQP One, Inc. press release
Axios
03-06-2025
- General
- Axios
Scoop: UTA to skip Utah Pride and all 2025 festivals during review
For the first time since 2022, the Utah Transit Authority will skip the Utah Pride Festival, following a pause on all festival and parade participation for the remainder of the year. Why it matters: Utah GOP lawmakers have previously expressed concerns over UTA's participation in the state's largest annual LGBTQ+ celebration. In 2023, text messages revealed some of them urged UTA to pull a rainbow-decorated bus that was set to appear in the parade. State of play: UTA spokesperson Gavin Gustafson told Axios that sitting out this year's events is necessary to "conduct a comprehensive review of our fare agreements, ensuring consistency and responsible stewardship of public funds." Gustafson said UTA board members and administrators made the decision in April and that it's centered on Ticket as Fare agreements, which allow tickets to approved events to serve as UTA passes. Zoom in: Axios obtained an April 2 email sent to senior leadership by executive director Jay Fox calling for the immediate cancellation of "all current agreements, plans, purchases, or discussions related to any UTA festival and parade participation this year." The email said the agency plans to provide a report in October to state lawmakers detailing the agreements and "their value." It also included talking points and guidance for responding to questions around the directive because it "may raise questions and concerns," and it told management to expect employee disappointment over the decision.
